Current and future perspectives on the TARGET system: the registration system for Glivec® established by the JSH
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Since hematology is a highly specialized field, an individual physician may not have much direct treatment experience with a given disease. Therefore, the Japanese Society of Hematology (JSH) has discussed establishing a registry of hematologic disorders, in order to contribute to improving the quality of treatments and clinical outcomes in this field. As a first step, the Timely and Appropriate Registration System for GLIVEC Therapy (TARGET), a registration system for chronic myeloid leukemia (CML) patients treated with imatinib, was established in October 2003. We present the preliminary results of the first 4 years’ experience with this system. CML patients treated with imatinib in Japan were registered through the website and the patient’s clinical course, including parameters and events like imatinib dose, blood counts, adverse events, and efficacy were recorded in months 1, 3, 6, 9, and 12 and then every 6 months thereafter. By September 2007, 862 patients from 176 hospitals were registered. Follow-up period was 0–54 months, and 127 patients were followed-up for more than 36 months. Based on these cumulative data, present imatinib treatment trends were analyzed and safety and efficacy were compared with international trial data.
- Cancer Incidence in Five Countries, vol VIII, Parkin DM, et al., eds. IARC Press, Lyon, 2002.
- O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994–1004. doi:10.1056/NEJMoa022457. CrossRef
- Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408–17. doi:10.1056/NEJMoa062867. CrossRef
- Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or intereferon α plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349:1423–32. doi:10.1056/NEJMoa030513. CrossRef
- Kerkela R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006;12:908–16. doi:10.1038/nm1446. CrossRef
- Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038–42. doi:10.1056/NEJM200104053441402. CrossRef
- Kantarjian HM, Talpatz M, Giles F, O’Brien S, Cortes J. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med. 2006;145:913–23.
- Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293:867–80. doi:10.1126/science.1062538. CrossRef
- Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354:2542–51. doi:10.1056/NEJMoa055104. CrossRef
- Talpatz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354:2531–41. doi:10.1056/NEJMoa055229. CrossRef
- Quintas-Cardama A, Kantarjian H, Jones D, et al. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood. 2007;107:497–9. doi:10.1182/blood-2006-07-035493. CrossRef
- Cortes J, Rousselot P, Kim DW, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood. 2006 (Epub ahead of print).
- Current and future perspectives on the TARGET system: the registration system for Glivec® established by the JSH
International Journal of Hematology
Volume 88, Issue 4 , pp 409-417
- Cover Date
- Print ISSN
- Online ISSN
- Springer Japan
- Additional Links
- IRIS study
- Industry Sectors
- Author Affiliations
- 1. Department of Hematology, Saitama Medical Center, Saitama Medical University, 1981 Kamoda, Kawagoe, Saitama, 350-8550, Japan
- 2. Division of Hematology, Keio University School of Medicine, Tokyo, Japan
- 3. First Department of Internal Medicine, Tokyo Medical University, Tokyo, Japan
- 4. Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
- 5. Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
- 6. Division of Hematology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan
- 7. Hematology Division, Department of Medicine, Hyogo Cancer Center, Hyogo, Japan
- 8. Department of Hematology, Oita Prefectural Hospital, Oita, Japan
- 9. Clinical Hematology and Clinical Diagnosis, Graduate School of Medicine, Osaka City University, Osaka, Japan
- 10. Department of Hematology, Osaka Red Cross Hospital, Osaka, Japan
- 11. Department of Hematology, NTT Japan Kyushu Hospital, Kumamoto, Japan
- 12. Division of Hematology, Department of Internal Medicine, Juntendo University School of Medicine, Tokyo, Japan